NuCana plc (N04A.F)

0,2100 0,0000 (0,00%) In data: 09:38AM CEST. Mercato aperto.

NuCana plc

3 Lochside Way
Edinburgh EH12 9DT
United Kingdom
44 13 1357 1111
https://www.nucana.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 25

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Hugh Stephen Griffith	Founder, CEO & Executive Director	1,14M	N/D	1968
Mr. Donald Munoz	Chief Financial Officer	N/D	N/D	1969
Mr. David Harrison	Head of Translational Medicine	N/D	N/D	1960
Dr. Jeffrey D. Bloss F.A.C.O.G., M.D.	Chief Medical Officer	N/D	N/D	1958
Ms. Theresa Bruce	Senior Vice President of Clinical Operations	N/D	N/D	N/D
Ms. Elisabeth Oelmann	Senior Vice President of Medical & Clinical Development	N/D	N/D	N/D
Martin Quinn	Company Secretary	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. The company applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing medicines, ProTides, to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil, which is in a Phase 1b/2 study in patients with metastatic colorectal cancer. The company also initiated a randomized Phase 2 study of NUC-3373, in combination with other agents, for the second-line treatment of patients with advanced colorectal cancer; and initiated a Phase 1b/2 modular study of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer. Its pipeline also comprises NUC-7738, a transformation of 3'-deoxyadenosine that is in the Phase 2 part of a Phase 1/2 study in patients with advanced solid tumors which is evaluating NUC-7738 as a monotherapy and in combination with pembrolizumab. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Governance aziendale

L'ISS Governance QualityScore di NuCana plc al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.